Sunshine Biopharma Inc. Overview
Pro stress-test →Sunshine Biopharma is a pharmaceutical company specializing in generic and specialty prescription medications. The company currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026.
Strategic Profile
Pro stress-test →Sunshine Biopharma is conducting a proprietary drug development program comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and a PLpro protease inhibitor. The company is focused on building a diversified generic pharmaceutical portfolio in Canada while advancing oncology and antiviral therapeutics.
Competitive Landscape
Pro stress-test →Sunshine Biopharma competes in the generic pharmaceutical space primarily against established Canadian and North American generic manufacturers such as Sandoz, Mylan (now part of Viatris), and Teva. The company's scale and pipeline are significantly smaller than these competitors. In specialty/oncology segments, the company faces competition from Gilead, Merck, and Bristol Myers Squibb on the branded side.
Industry Context
Sunshine Biopharma Inc. operates in Pharmaceutical Manufacturing - Generic & Specialty.
Key facts
Headquarters: Fort Lauderdale, FL, US · Revenue: $5.6M (Q2 2023, pre-split) · Market cap: N/A